ArticleEuropean radiology2026
Microwave ablation versus surgical resection for unifocal T1aN0M0 papillary thyroid carcinoma: a 10-year follow-up study.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesTo evaluate the long-term oncological outcomes and safety of ultrasound-guided microwave ablation (MWA) compared to surgical resection (SR) for unifocal T1aN0M0 papillary thyroid carcinoma (PTC). MATERIALS AND
methodsThis single-center retrospective analysis enrolled 134 patients with unifocal T1aN0M0 papillary thyroid carcinoma who underwent either ultrasound-guided MWA or SR between June and October 2014. Baseline demographic and clinical characteristics were well-balanced between the two cohorts. Primary endpoints included local tumor recurrence, new tumor, distant metastasis, and lymph node metastasis. Secondary endpoints comprised the volume reduction rate of the ablation zone and the incidence of procedure-related complications.
resultsA total of 134 patients (mean age 43.53 ± 9.19 years, 99 females) were included in this study and followed for a complete period of 120 months. No statistically significant difference was observed in disease progression-free survival between the MWA and SR groups. The MWA group demonstrated a numerically lower overall complication rate compared to the SR group, with the majority of complications being transient. Permanent complications occurred only in the SR group.
conclusionLong-term follow-up suggests that ultrasound-guided MWA could be considered a safe and effective therapeutic choice in addition to SR for selected patients with unifocal T1aN0M0 PTC. KEY POINTS: Question What are the 10-year outcomes of ultrasound-guided MWA versus SR in patients with unifocal T1aN0M0 papillary thyroid carcinoma? Findings During long-term follow-up of patients treated with ultrasound-guided MWA, normal thyroid function was preserved without thyroid hormone replacement therapy. No permanent procedure-related complications were documented in the observation period. Clinical relevance These findings suggest that MWA could be considered as a treatment option in addition to SR for selected patients with unifocal T1aN0M0 PTC, potentially enabling a less invasive management approach. Further investigation is warranted to validate these preliminary results.
Indexed as
Identifiers
42470479What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.